

Gene Therapy

Part I: Technologies & Markets

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

April 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech. Prof. Jain's 474 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (2008, 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer 2008; Chinese edition, Peking University Press 2011; 3rd ed Springer 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition. Chemical Industry Press 2016, 2nd ed Springer 2017) and "Handbook of Neuroprotection" (Springer 2011). Books that contain chapters on gene therapy include: Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and Applications of Biotechnology in Oncology (Springer 2014). He has also edited "Applied Neurogenomics" (Springer in 2015).

A B O U T T H I S R E P O R T

Prof. Jain wrote the first commercial report on Gene Therapy in 1995, which was published by PJB Publication, London. This was followed by reports on Gene Therapy Vectors and Cancer Gene Therapy (1996). A report on Gene Therapy of Neurological Disorders was published by Decision Resources in 1997. In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003. In 2004, when the copyright reverted to Prof. Jain, it became part II of the Gene Therapy report. This report supercedes and updates all the previous books as well as reports.

April 2018
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	21
1. Introduction	23
Definitions	23
Historical evolution of gene therapy	23
Relation of gene therapy to other biotechnologies.....	25
Molecular biological basics for gene therapy	26
Genome.....	26
DNA	26
RNA	27
<i>Alternative RNA splicing.....</i>	<i>28</i>
Genes.....	28
<i>Silent gene mutations.....</i>	<i>29</i>
Gene regulation	29
Gene expression	30
ENCODE	31
Chromosomes	31
Telomeres.....	32
Mitochondria	32
Proteins	33
2. Gene Therapy Technologies	35
Classification of gene therapy techniques.....	35
Ex vivo and in vivo gene therapy	36
Ex vivo gene therapy.....	36
In vivo gene therapy	37
Physical methods of gene transfer.....	37
Electroporation	37
Applications of electroporation	38
<i>Clinical applications of electroporation</i>	<i>39</i>
<i>Advantages of electroporation</i>	<i>40</i>
<i>Limitations of electroporation</i>	<i>40</i>
Hydrodynamic	40
Microinjection.....	41
Particle bombardment	41
Ultrasound-mediated transfection	43
Molecular vibration.....	44
Application of pulsed magnetic field and superparamagnetic nanoparticles	44
Gene transfection using laser irradiation	44
Photochemical transfection.....	45
Chemical methods of gene transfer	45
Gene repair and replacement.....	45
Gene repair by single-stranded oligonucleotides.....	46
History and current status of chimeraplasty	46
Genome editing.....	46
Gene editing by zinc finger nucleases.	46
Gene editing by using short synthetic oligonucleotides.....	47
Genome engineering by using TALENs	47
Gene editing by homing endonucleases	47
Genome editing by using CRISPR system	48
<i>A method for generating genome-wide gRNA libraries for CRISPR</i>	<i>49</i>
<i>CRISPR vs other gene editing tools</i>	<i>49</i>
<i>CRISPR for studying human embryogenesis</i>	<i>50</i>
<i>CRISPR for correction of a gene mutation in the human embryo</i>	<i>50</i>
<i>CRISPR system for creating animal models of human diseases.....</i>	<i>51</i>
<i>CRISPR/Cas9 technology for drug discovery</i>	<i>51</i>
<i>Expanding the range of Cas9s</i>	<i>51</i>
<i>Inducible CRISPR/Cas9 for multiple gene targeting</i>	<i>52</i>
<i>Photoactivatable CRISPR-Cas9.....</i>	<i>52</i>
<i>Protein delivery and genome editing.....</i>	<i>52</i>
<i>Potential clinical applications of CRISPR systems.....</i>	<i>53</i>
<i>PERV blockage by CRISPR to facilitate xenotransplantation</i>	<i>54</i>
<i>RNA editing with CRISPR.....</i>	<i>54</i>
<i>Use of CRISPR to restore hereditary hearing loss</i>	<i>55</i>
<i>Clinical trial of CRISPR in human cancer.....</i>	<i>56</i>
<i>Complications and limitations of CRISPR/Cas9 technology.....</i>	<i>57</i>
<i>Companies developing CRISPR technology</i>	<i>57</i>

Targeted genome editing by artificial nucleases	58
Clinical applications of gene editing	58
Future gene editing tools	59
Base editing of the genome	59
Base editing by protein engineering.....	60
Adenine base editors for genomic DNA	60
mRNA gene therapy	60
Spliceosome mediated RNA trans-splicing	61
Vectors for gene therapy	61
Basic considerations	61
Use of genes as pharmaceuticals	62
The ideal vector for gene therapy.....	62
Viral vectors.....	62
<i>Adenovirus vectors</i>	63
<i>Adeno-associated virus vectors</i>	65
<i>Alphavirus vectors</i>	68
<i>Baculovirus vectors</i>	69
<i>Foamy virus vectors</i>	69
<i>Herpes simplex virus vectors</i>	69
<i>Lentiviral vectors</i>	72
<i>Multicistronic retroviral vectors</i>	72
<i>Retroviral vectors</i>	73
<i>Oncogenic potential of retroviral vectors</i>	74
<i>Quantification of viral vectors</i>	75
<i>Future of viral vectors</i>	75
<i>Companies using viral vectors</i>	76
Nonviral vectors for gene therapy	77
<i>Anionic lipid-DNA complexes</i>	78
<i>Cationic lipid-DNA complexes</i>	78
<i>Effects of shape of DNA molecules on delivery with nonviral vectors</i>	78
<i>Electrostatic modifications of surface to improve gene delivery</i>	79
<i>Liposomes for gene therapy</i>	79
<i>Liposome-nucleic acid complexes</i>	81
<i>Liposome-HVJ complex</i>	81
<i>Transposons DNA vectors</i>	81
<i>Polycation-DNA complexes (polyplexes)</i>	82
<i>Plasmid DNA vs minicircle DNA</i>	83
<i>Polymer vectors for gene therapy</i>	84
<i>Synthetic biology and DNA vectors</i>	84
<i>Synthetic peptide complexes</i>	85
<i>Future of nonviral vs viral vectors</i>	85
Nanobiotechnology for gene therapy	86
<i>Antisense nanoparticles</i>	86
<i>Dendrimers</i>	86
<i>Cochleates</i>	87
<i>Calcium phosphate nanoparticles as nonviral vectors</i>	87
<i>DNA nanoparticles as nonviral vectors</i>	87
<i>Gelatin nanoparticles for gene delivery</i>	87
<i>Lipid nanoparticles for nucleic acid delivery</i>	88
<i>Lipid nanoparticles for delivery of genome-editing proteins</i>	88
<i>Nanoparticles as nonviral vectors for gene therapy</i>	88
<i>Nanoparticles with virus-like function as gene therapy vectors</i>	89
<i>Nanobiologics for nucleic acid delivery</i>	89
<i>Nonionic polymeric micelles for oral gene delivery</i>	89
<i>Silica nanoparticles as a nonviral vector for gene delivery</i>	90
<i>Virus-like particles as nonviral vector</i>	90
Receptor-mediated endocytosis	90
Artificial viral vectors.....	91
Directed evolution of AAV to create efficient gene delivery vectors	92
Bacterial ghosts as DNA delivery systems	92
Bacteria plus nanoparticles for gene delivery into cells.....	93
Chromosome-based vectors for gene therapy	93
<i>Mammalian artificial chromosomes (MACs)</i>	94
<i>Human artificial chromosomes (HACs)</i>	94
<i>ΦC31 integrase system</i>	95
Companies using nonviral vectors	95
Concluding remarks about vectors	96
Cell-mediated gene therapy	97
Fibroblasts	97
Skeletal muscle cells	98
Vascular smooth muscle cells	99

Keratinocytes	99
Hepatocytes	99
Lymphocytes	99
<i>Regulating protein delivery by genetically encoded lymphocytes</i>	<i>100</i>
Implantation of microencapsulated genetically modified cells	100
Stem cell gene therapy	101
<i>Therapeutic applications for hematopoietic stem cell gene transfer.....</i>	<i>101</i>
<i>Improving delivery of genes to stem cells</i>	<i>101</i>
<i>Lentiviral vectors for gene transfer to marrow stem cells</i>	<i>102</i>
<i>Use of mesenchymal stem cells for gene therapy</i>	<i>102</i>
<i>Microporation for transfection of MSCs.....</i>	<i>102</i>
<i>In utero gene therapy using stem cells</i>	<i>102</i>
<i>Gene delivery to stem cells by artificial chromosome expression</i>	<i>103</i>
<i>Linker based sperm-mediated gene transfer technology.....</i>	<i>103</i>
<i>Combination of gene therapy with therapeutic cloning</i>	<i>103</i>
<i>Expansion of transduced HSCs in vivo</i>	<i>103</i>
<i>The future of hematopoietic stem cell gene therapy</i>	<i>104</i>
Role of genetically modified bacteria in gene therapy	104
Routes of administration for gene therapy	105
Direct injection of naked DNA	105
Intramuscular injection	106
Intravenous DNA injection	106
Intraarterial delivery	106
Companies with gene delivery devices/technologies	106
Targeted gene therapy.....	107
Targeted integration.....	108
Bacteriophage integrase system for site-specific gene delivery	108
Controlled-release delivery of DNA	109
Controlled gene therapy	109
Controlled delivery of genetic material.....	109
Controlled induction of gene expression	110
Drug-inducible systems for control of gene expression.....	110
Timed activation of gene therapy by a circuit based on signaling network	111
Small molecules for post-transcriptional regulation of gene expression	111
Light Activated Gene Therapy.....	111
Spatial control of gene expression via local hyperthermia.....	112
Companies with regulated /targeted gene therapy	112
Gene marking	113
Germline gene therapy	113
Potential applications of human germline genome modification	113
Pros and cons of human germline genome modification	114
Role of gene transfer in antibody therapy.....	115
Genetically engineered vaccines	116
DNA vaccines	116
<i>DNA inoculation technology.....</i>	<i>116</i>
<i>Methods for enhancing the potency of DNA vaccines</i>	<i>117</i>
<i>Advantages of DNA vaccines</i>	<i>117</i>
Vaccine vectors	118
Challenges and limitations of genetically engineered vaccines.....	119
RNA vaccines.....	119
<i>Nonviral delivery of self-amplifying RNA vaccine</i>	<i>119</i>
Vaccines based on reverse genetics.....	119
Technologies for gene suppression	120
Antisense oligonucleotides	120
Transcription factor decoys	120
Aptamers.....	121
Ribozymes	121
Peptide nucleic acid.....	122
<i>Intracellular delivery of PNAs.....</i>	<i>122</i>
Locked nucleic acid	122
<i>Zorro-LNA.....</i>	<i>123</i>
Gene silencing	123
Post-transcriptional gene silencing	123
Definitions and terminology of RNAi	124
RNAi mechanisms	124
Inhibition of gene expression by antigenic RNA	125
RNAi gene therapy	125
microRNA gene therapy	125
Viral vectors for RNAi and miRNA gene therapy	125
Application of molecular diagnostic methods in gene therapy	127
Use of PCR to study biodistribution of gene therapy vector	127

PCR for verification of the transcription of DNA	127
In situ PCR for direct quantification of gene transfer into cells	128
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	128
Confirmation of viral vector integration.....	128
Monitoring of gene expression	128
<i>Monitoring of gene expression by green fluorescent protein.....</i>	<i>128</i>
<i>Monitoring in vivo gene expression by molecular imaging.....</i>	<i>129</i>
<i>Advantages of gene therapy compared with protein therapy.....</i>	<i>129</i>
Formulation, transport and storage of materials for gene therapy	130

3. Clinical Applications of Gene Therapy	131
Introduction	131
Aging research.....	131
Bone and joint disorders.....	131
Bone fractures.....	131
Gene therapy for intervertebral disc degeneration.....	132
Spinal fusion	133
Osteogenesis imperfecta	133
Rheumatoid arthritis.....	134
<i>Local or systemic treatment</i>	<i>134</i>
<i>In vivo or ex vivo gene therapy of RA.....</i>	<i>134</i>
<i>Clinical trials of gene therapy for rheumatoid arthritis.....</i>	<i>135</i>
Gene therapy for osteoarthritis.....	136
<i>Gene therapy strategies for osteoarthritis</i>	<i>136</i>
<i>Clinical trials of gene therapy for osteoarthritis</i>	<i>138</i>
Sports injuries.....	138
<i>Repair of articular cartilage defects</i>	<i>138</i>
Regeneration and replacement of bone by gene therapy	139
Bacterial infections	140
Antisense approach to bacterial infections	140
Dentistry.....	140
Tissue engineering in dental implant defects	140
Endocrine and metabolic disorders	141
Introduction	141
Gene therapy of obesity.....	141
<i>AAV vector-mediated delivery of GDNF for obesity</i>	<i>141</i>
<i>Oligopeptide for targeted nonviral gene delivery to adipocytes.....</i>	<i>142</i>
<i>Viral vector-mediated leptin gene therapy.....</i>	<i>142</i>
Diabetes mellitus	143
Methods of gene therapy of diabetes mellitus	143
<i>Viral vector-mediated gene transfer in diabetes</i>	<i>144</i>
<i>Endogenous reprogramming of α cells into β cells</i>	<i>145</i>
<i>Gene delivery with ultrasonic microbubble destruction technology.....</i>	<i>145</i>
<i>Genetically engineered cells for diabetes mellitus.....</i>	<i>145</i>
<i>Genetically altered liver cells</i>	<i>146</i>
<i>Genetically modified stem cells.....</i>	<i>146</i>
<i>Genetically engineered dendritic cells</i>	<i>146</i>
<i>Glucokinase and insulin co-expression</i>	<i>146</i>
<i>Leptin gene therapy</i>	<i>147</i>
<i>Concluding remarks about cell and gene therapy of diabetes</i>	<i>147</i>
Gene therapy of growth-hormone deficiency	148
Gastrointestinal disorders.....	149
Introduction	149
Methods of gene transfer to the gastrointestinal tract.....	149
<i>Direct delivery of genes</i>	<i>149</i>
<i>Naked plasmid DNA into the submucosa</i>	<i>149</i>
<i>Viral vectors.....</i>	<i>149</i>
<i>Receptor-mediated endocytosis</i>	<i>150</i>
Indications for gastrointestinal gene therapy	150
<i>Gene therapy for inflammatory disorders of the bowel.....</i>	<i>151</i>
Gene transfer to the salivary glands.....	151
<i>Potential clinical applications of salivary gene therapy</i>	<i>152</i>
Hematology	152
Hemophilias	152
<i>Gene therapy of hemophilia</i>	<i>153</i>
<i>Hemophilia A.....</i>	<i>154</i>
<i>Hemophilia B.....</i>	<i>155</i>
<i>Concluding remarks about gene therapy of hemophilias.....</i>	<i>157</i>
Hemoglobinopathies	157
<i>Gene therapy for β-thalassemia</i>	<i>158</i>
<i>Gene therapy for sickle cell disease.....</i>	<i>159</i>

Gene therapy and RNAi for SCD based on stem cells	159
Gene editing in sickle cell disease	160
Gene editing using ZFN as treatment for both SCD and β -thalassemia	160
Gene editing using CRISPR-Cas9 for both SCD and β -thalassemia	161
Gene therapy of Fanconi's anemia	161
Acquired hematopoietic disorders	162
Chronic acquired anemias	162
Neutropenia	162
Thrombocytopenia	163
Concluding remarks about gene therapy of hemoglobinopathies	164
Companies involved in gene therapy of hematological disorders	164
In utero/fetal gene therapy	164
Fetal gene transfer techniques	165
Animal models of fetal gene therapy	166
Potential applications of fetal gene therapy	166
Fetal gene therapy for cystic fibrosis	166
Fetal intestinal gene therapy	167
Gene therapy for fetal growth restriction	167
Hearing disorders	167
Potential of gene therapy	168
Vectors for gene therapy of hearing disorders	168
Auditory hair cell replacement and hearing improvement by gene therapy	169
Kidney diseases	169
End-stage renal disease	169
Methods of gene delivery to the kidney	170
Gene transfer into kidney by adenoviral vectors	170
Non-viral gene transfer to the kidneys	170
Gene transfer into the glomerulus by HVJ-liposome	171
Bone marrow stem cells for renal disease	171
Mesangial cell therapy	171
Liposome-mediated gene transfer into the tubules	172
Gene transfer to tubules with cationic polymer polyethylenimine	172
Gene therapy in animal experimental models of renal disease	172
Genetic manipulations of the embryonic kidney	173
Antisense intervention in glomerulonephritis	173
Gene therapy for renal fibrosis	173
Use of genetically engineered cells for uremia due to renal failure	174
Concluding remarks	174
Liver disorders	174
Techniques of gene delivery to liver	175
Direct injection of DNA into liver	175
Local gene delivery by isolated organ perfusion	176
Liposome-mediated direct gene transfer	176
Retroviral vector for gene transfer to liver	176
Adenoviral vectors for gene transfer to liver	176
Receptor-mediated approach	177
Cell therapy for liver disorders	177
Transplantation of genetically modified hepatocytes	177
Genetically modified hematopoietic stem cells	177
Gene therapy by ex vivo transduced liver progenitor cells	178
Gene therapy of genetic diseases affecting the liver	178
Crigler-Najjar syndrome	178
Hereditary tyrosinemia type I (HT1)	178
Hereditary tyrosinemia type 3	179
Gene therapy of acquired diseases affecting the liver	179
Cirrhosis of liver	179
Ophthalmic disorders	180
Introduction to gene therapy of ophthalmic disorders	180
Methods of gene therapy for ophthalmic disorders	181
Delivery of gene therapy by intravitreal injection	182
DNA nanoparticles for nonviral gene transfer to the eye	182
Optogenetic gene therapy for blindness due to retinal degeneration	183
Age-related macular degeneration	183
Inherited disorders of optic nerve affecting vision	184
Leber hereditary optic neuropathy	185
Gene therapy for LHON	185
Inherited retinal degenerations	186
Choroideremia	187
Leber congenital amaurosis	187
Retinitis pigmentosa	189
Stargardt disease	190

Other inherited disorders affecting vision	191
<i>Color blindness</i>	191
<i>Usher syndrome</i>	191
<i>X-linked retinoschisis</i>	193
Diabetic retinopathy	193
Future of gene therapy of inherited retinal degenerations	193
<i>Combining cell and gene therapies for retinal disorders</i>	194
Prevention of complications associated with eye surgery	194
<i>Prevention of proliferative retinopathy by gene therapy</i>	194
<i>Posterior capsule opacification after cataract surgery</i>	194
Autoimmune uveitis	195
Retinal ischemic injury.....	195
Corneal disorders.....	195
Glaucoma	196
Corneal scarring	196
Companies developing gene therapy for eye disorders.....	196
Organ transplantation.....	197
Introduction	197
DNA vaccines for transplantation	197
Gene therapy for prolonging allograft survival	197
<i>Genetically modified Tregs expressing CAR for preventing GVHD</i>	198
Gene therapy in lung transplantation.....	198
Role of gene therapy in liver transplantation	199
Gene therapy in kidney transplantation.....	199
Veto cells and transplant tolerance.....	199
Pulmonary disorders.....	200
Techniques of gene delivery to the lungs	200
<i>Adenoviral vectors</i>	201
<i>Nonviral vectors</i>	201
<i>Aerosolization as an aid to gene transfer to lungs.</i>	202
Cystic fibrosis.....	202
<i>Genetics and clinical features</i>	202
<i>Gene therapy for CF</i>	202
<i>CFTR gene transfer in CF</i>	203
<i>Concluding remarks about gene therapy of CF</i>	204
Miscellaneous pulmonary disorders	204
<i>Gene therapy for pulmonary arterial hypertension</i>	205
<i>Gene therapy for bleomycin-induced pulmonary fibrosis</i>	205
<i>Gene therapy of emphysema due to α1-antitrypsin deficiency</i>	206
<i>Gene therapy for asthma</i>	206
<i>Gene therapy for adult respiratory distress syndrome</i>	207
<i>Gene therapy for lung injury</i>	207
<i>Gene therapy for bronchopulmonary dysplasia</i>	207
Concluding remarks about gene therapy of lungs.....	208
Companies involved in pulmonary gene therapy	208
Skin and soft tissue disorders.....	209
Gene transfer to the skin	209
<i>Electroporation for transdermal delivery of plasmid DNA</i>	209
<i>Electroporation for transdermal delivery of DNA vaccines</i>	210
<i>Liposomes for transdermal gene delivery</i>	210
<i>Ultrasound and topical gene therapy</i>	210
Gene therapy in skin disorders	210
<i>Gene therapy of hair loss</i>	211
<i>Gene therapy for epidermolysis bullosa</i>	211
<i>Gene therapy for xeroderma pigmentosa</i>	213
<i>Gene therapy for lamellar ichthyosis</i>	213
Gene transfer techniques for wound healing	213
Urogenital disorders	214
Gene therapy for urinary tract dysfunction	214
Gene therapy for erectile dysfunction	214
<i>NOS gene transfer for erectile dysfunction</i>	214
<i>Clinical trial of hMaxi-K Gene transfer in erectile dysfunction</i>	215
<i>Gene therapy for erectile dysfunction due to nerve injury</i>	215
<i>Concluding remarks on gene therapy for erectile dysfunction</i>	215
Veterinary gene therapy	215
Gene therapy for mucopolysaccharidosis VII in dogs	216
Gene therapy to increase disease resistance.....	216
Gene therapy for infections	216
Gene therapy for chronic anemia	217
Gene therapy for endocrine disorders	217
Gene therapy for arthritis.....	217

Cancer gene therapy	218
<i>Brain tumors in cats and dogs</i>	218
<i>Breast cancer in dogs</i>	218
<i>Canine hemangiosarcoma</i>	219
<i>Canine melanoma</i>	219
<i>Canine soft tissue sarcoma</i>	220
Melanoma in horses	220
4. Gene Therapy of Genetic Disorders	221
Introduction	221
Primary immunodeficiency disorders	222
Severe combined immune deficiency	223
Chronic granulomatous disease	226
Wiskott-Aldrich syndrome	226
Purine nucleoside phosphorylase deficiency	227
Major histocompatibility class II deficiency	227
Future prospects of gene therapy of inherited immunodeficiencies	228
Metabolic disorders	228
Alpha1-antitrypsin deficiency	229
<i>AAV mediated gene therapy for α1-antitrypsin deficiency</i>	229
<i>iPSCs for targeted gene correction of α1-antitrypsin deficiency</i>	230
Adrenoleukodystrophy	231
Canavan disease	232
Lesch-Nyhan syndrome	233
Lipoprotein lipase deficiency	233
<i>Alipogene tiparvovec</i>	233
Ornithine transcarbamylase deficiency	234
<i>Gene therapy for OTCD</i>	234
<i>AAV-mediated gene editing for OTCD using CRISPR-Cas9</i>	235
Phenylketonuria	235
Porphyrias	236
Tetrahydrobiopterin deficiency	237
Lysosomal storage disorders	237
Batten disease	238
Fabry's disease	239
Farber's disease	239
Gaucher disease	239
<i>Animals models of Gaucher's disease</i>	240
<i>Gene therapy of Gaucher's disease</i>	240
Hunter syndrome	241
Krabbe's disease	241
Metachromatic leukodystrophy	242
Mucopolysaccharidosis type 1 (Hurler syndrome)	243
Niemann-Pick type A disease	244
Pompe disease	244
Sanfilippo A syndrome	245
Sly syndrome	245
Tay-Sachs disease	246
Future prospects of gene therapy of lysosomal storage disorders	246
Trinucleotide repeat disorders	247
Muscular dystrophies	247
Duchenne muscular dystrophy (DMD)	247
<i>Animal models for gene therapy of DMD</i>	248
<i>Antisense approaches to DMD</i>	248
<i>CRISPR/Cas9 gene editing for DMD</i>	248
<i>Exon-skipping for DMD</i>	249
<i>Galgt2 gene therapy</i>	250
<i>Liposome-mediated gene transfer</i>	250
<i>Microdystrophin gene therapy</i>	250
<i>Myoblast-based gene transfer in DMD</i>	251
<i>Plasmid-mediated gene therapy</i>	251
<i>Purinoreceptor P2RX7 ablation</i>	251
<i>Post-transcriptional modulation of gene expression in DMD</i>	252
<i>Repair/Editing of dystrophin gene</i>	252
<i>Routes of administration of gene therapy in DMD</i>	255
<i>Types of dystrophin constructs</i>	256
<i>Viral vectors for DMD</i>	256
<i>Conclusions and future of gene therapy of DMD</i>	257
Limb-girdle muscular dystrophy	258
Myotonic dystrophy	258
Spinal muscular atrophy	259

Gene therapy for SMA	259
Antisense therapy of SMA	260
Nusinersen	260
Nusinersen vs scAAV9 gene therapy for SMA	261
X-linked myotubular myopathy (XLMTM)	261
Hereditary neuropathies	261
Charcot-Marie-Tooth disease	261
Hereditary axonal neuropathies of the peripheral nerves	262
Gene therapy of mitochondrial disorders	262
Techniques for mitochondrial replacement therapy	263
Status of mitochondrial replacement and transfer therapies	264
Companies involved in gene therapy of genetic disorders	265
5. Gene Therapy of Cancer	267
Strategies for cancer gene therapy	267
Direct gene delivery to the tumor	268
Injection into tumor	268
Direct injection of adenoviral vectors	268
Direct injection of a plasmid DNA-liposome complex	269
A polymer approach to local gene therapy for cancer	269
Electroporation for cancer gene therapy	269
Control of gene expression in tumor by local heat	270
Radiation-guided gene therapy of cancer	270
Radioprotective gene therapy of cancer	270
Nanoparticles to facilitate combination of hyperthermia and gene therapy	271
Immunogene therapy of cancer	271
Cell-based cancer gene therapy	272
Adoptive cell therapy	272
Cytokine gene therapy	273
Genetic modification of human hematopoietic stem cells	275
Cancer vaccines	276
Genetically modified cancer cell vaccines	276
GVAX cancer vaccines	276
Genetically modified dendritic cells	277
Nucleic acid-based cancer vaccines	277
DNA cancer vaccines	278
RNA vaccines	278
Viral vector-based cancer vaccines	278
Intradermal delivery of cancer vaccines by Ad vectors	279
Vaccines based on genetically engineered nonviral vectors	279
Future of cancer vaccines	279
Companies involved in nucleic acid-based cancer vaccines	280
Monoclonal antibody gene transfer for cancer	281
Transfer and expression of intracellular adhesion-1 molecules	281
Other gene therapy techniques for immunotherapy of cancer	281
Chemokines	281
CRISPR for immunogene therapy	282
Engineered viruses as anticancer immunotherapy vectors	283
Fas (Apo-1)	283
Major Histocompatibility Complex (MHC) Class I	283
IGF (Insulin-Like Growth Factor)	283
Cancer immunotherapies targeting multiple mechanisms	283
Inhibition of immunosuppressive function in cancer	284
Delivery of toxic genes to tumor cells for eradication	284
Gene-directed enzyme prodrug therapy	284
Combination of gene therapy with radiotherapy	285
Correction of genetic defects in cancer cells	285
Targeted gene therapy for cancer	286
Antiangiogenic therapy for cancer	286
Bacteria as novel anticancer gene vectors	287
Cancer-specific gene expression	287
Cancer-specific transcription	287
Delivery of retroviral particles hitchhiking on T cells	288
Electrogene and electrochemotherapy	288
Epidermal growth factor-mediated DNA delivery	288
Gene expression in hypoxic tumor cells	289
Genetically modified T cells for targeting tumors	289
Chimeric antigen receptor T cells	290
CAR-T cells targeting both CD19 and CD22	292
Remote control of CAR-T cells	292
Genetically engineered stem cells for targeting tumors	293

Hematopoietic stem cells for targeted cancer gene therapy	293
Immunolipoplex for delivery of p53 gene	294
Nanomagnets for targeted cell-based cancer gene therapy	294
Nanoparticles for targeted site-specific delivery of anticancer genes	294
Targeted cancer therapy using a dendrimer-based synthetic vector	295
Tumor-targeted gene therapy by receptor-mediated endocytosis	295
Virus-mediated oncolysis	295
Cytokine-induced killer cells for delivery of an oncolytic virus	296
Monitoring of viral-mediated oncolysis by PET	296
Oncolytic adenoviruses	296
Oncolytic HSV	298
Oncolytic measles viruses	298
Oncolytic vaccinia virus	299
Oncolytic vesicular stomatitis virus	299
Targeted cancer treatments based on oncolytic viruses	299
Concluding remarks on oncolytic gene therapy	300
<i>Companies developing oncolytic viruses</i>	300
Apoptotic approach to improve cancer gene therapy	301
Tumor suppressor gene therapy	302
P53 gene therapy	302
BRIT1 gene therapy	302
Nitric oxide-based cancer gene therapy	302
Anticancer effect of nitric oxide synthase	302
Gene therapy for radiosensitization of cancer	303
Gene therapy of cancer of selected organs	303
Gene therapy for bladder cancer	303
Gene therapy for glioblastoma multiforme.	304
<i>Adenoviral vectors for treatment of brain tumors</i>	305
<i>Antiangiogenic gene therapy</i>	305
<i>Autophagy induced by conditionally replicating adenoviruses</i>	306
<i>Baculovirus vector for diphtheria toxin gene therapy</i>	306
<i>Cerepro® (sitimagene ceradenovec)</i>	306
<i>Gene therapy targeting hepatocyte growth factor</i>	307
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i>	307
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	307
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	308
<i>Olig2 targeting to hinder growth of treatment-resistant glioblastomas</i>	308
<i>RNAi gene therapy of brain cancer</i>	308
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	309
<i>Viral oncolysis of glioblastoma multiforme</i>	309
Gene therapy for breast cancer	311
<i>Gene vaccine for breast cancer</i>	311
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	312
Gene Therapy for ovarian cancer	312
Gene therapy for malignant melanoma	313
<i>Immunogene therapy</i>	313
<i>Nonviral immunogene therapy for malignant melanoma</i>	314
<i>Oncogene targeted therapy</i>	315
<i>Targeted gene therapy for malignant melanoma</i>	315
Gene therapy of lung cancer	315
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene</i>	315
<i>Aerosol gene delivery for lung cancer</i>	316
Gene therapy for cancer of prostate	316
<i>Experimental studies</i>	316
<i>Nanoparticle-based gene therapy for prostate cancer</i>	317
<i>Tumor suppressor gene therapy in prostate cancer</i>	317
<i>Vaccines for prostate cancer</i>	317
<i>Viral oncolysis for prostate cancer</i>	318
<i>Clinical trials of gene therapy for prostate cancer</i>	318
Gene therapy of head and neck cancer	318
<i>Adenoviral vector based P53 gene therapy</i>	318
<i>Gene therapy as adjunct to 5-FU for nasopharyngeal carcinoma</i>	319
Gene therapy of pancreatic tumors	319
<i>Pancreatic neuroendocrine tumors</i>	319
<i>Pancreatic ductal adenocarcinoma</i>	319
<i>Correction of altered genes</i>	320
<i>Targeted gene therapy</i>	320
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i>	321
<i>Targeted Expression of BikDD gene</i>	321
<i>Viral oncolysis in pancreatic cancer</i>	321
<i>Concluding remarks on gene therapy of pancreatic cancer</i>	322

Gene therapy of renal cancer.....	322
<i>Viral oncolytic therapy for renal cancer</i>	322
Gene therapy of hematological malignancies.....	322
<i>Genetically engineered T lymphocytes</i>	322
Cancer gene therapy companies	323

6. Gene Therapy of Neurological Disorders 327

Indications 327

Gene transfer techniques for the nervous system..... 328

Methods of gene transfer to the nervous system.....	328
Ideal vector for gene therapy of neurological disorders.....	328
Promoters of gene transfer.....	328
Lentivirus-mediated gene transfer to the CNS.....	329
AAV vector mediated gene therapy for neurogenetic disorders.....	329
Gene transfer to the CNS using recombinant SV40-derived vectors.....	330
Routes of delivery of genes to the nervous system.....	330
<i>Direct injection into CNS</i>	330
<i>Introduction of the genes into cerebral circulation</i>	331
<i>Introduction of genes into cerebrospinal fluid</i>	331
<i>Intravenous administration of vectors</i>	332
Delivery of gene therapy to the peripheral nervous system.....	332
Cell-mediated gene therapy of neurological disorders.....	332
<i>Neuronal cells</i>	332
<i>Neural stem cells and progenitor cells</i>	332
<i>Astrocytes</i>	333
<i>Cerebral endothelial cells</i>	333
<i>Implantation of genetically modified encapsulated cells into the brain</i>	333
Gene transfer for neuromodulation.....	334

Gene therapy of neurodegenerative disorders 334

Gene therapy for Parkinson disease.....	334
Rationale.....	335
<i>Techniques of gene therapy for PD</i>	335
<i>Augmenting CNS glucocerebrosidase activity</i>	339
<i>Delivery of neurotrophic factors by gene therapy</i>	339
<i>Delivery of parkin gene</i>	340
<i>Introduction of functional genes into the brain of patients with PD</i>	340
<i>Nanoparticle-based gene therapy for PD</i>	340
<i>Mitochondrial gene therapy for PD</i>	340
<i>RNAi approach to PD</i>	341
<i>Prospects of gene therapy for PD</i>	341
<i>Concluding remarks about gene therapy of PD</i>	342
<i>Companies developing gene therapy for PD</i>	342
Gene therapy for Alzheimer disease.....	343
Rationale.....	343
<i>NGF gene therapy for AD</i>	343
<i>FGF2 gene transfer in AD</i>	344
<i>Nepriylsin gene therapy</i>	345
<i>Targeting plasminogen activator inhibitor type-1 gene</i>	345
<i>Viral gene transfer of APP_{sw} for rescuing synaptic failure in AD</i>	345
<i>Gene vaccination</i>	346
<i>Combination of gene therapy with other treatments for AD</i>	346
Gene therapy of Huntington disease.....	346
<i>Encapsulated genetically engineered cellular implants</i>	346
<i>Viral vector mediated administration of neurotrophic factors</i>	347
<i>RNAi gene therapy</i>	347
Gene therapy of amyotrophic lateral sclerosis.....	347
Rationale.....	347
<i>Technique of gene therapy of ALS</i>	347
<i>Other approaches to gene therapy of ALS</i>	349

Gene therapy of cerebrovascular diseases 349

Preclinical research in gene therapy for cerebrovascular disease.....	349
Animal models of stroke relevant to gene therapy.....	349
<i>Transgenic mice as models for stroke</i>	350
<i>Animal models for gene therapy of arteriovenous malformations</i>	350
Gene transfer to cerebral blood vessels.....	350
Gene therapy for vasospasm following subarachnoid hemorrhage.....	351
<i>NOS gene therapy for cerebral vasospasm</i>	352
Gene therapy for stroke.....	352
<i>Gene therapy for stroke using neurotrophic factors</i>	354
<i>Gene therapy of strokes with a genetic component</i>	354
<i>Gene therapy for intracranial aneurysms</i>	354

<i>RNAi-based gene silencing for neuroprotection in cerebral ischemia</i>	355
Concluding remarks about gene therapy for stroke.....	355
Gene therapy of injuries to the nervous system.....	356
Traumatic brain injury	356
Spinal cord injury.....	356
Peripheral nerve injuries	357
Gene therapy of epilepsy	357
Gene therapy for control of seizures.....	358
Gene therapy for neuroprotection in epilepsy	359
Gene therapy for genetic forms of epilepsy	359
Gene therapy for multiple sclerosis	360
Gene therapy for impairment of special senses	360
Gene therapy for hearing loss.....	360
Gene therapy for olfactory impairment	361
Gene therapy for relief of pain	362
Rationale of gene therapy for pain	362
Vectors for gene therapy of pain	362
Methods of gene delivery for pain	362
<i>Endogenous analgesic production for cranial neuralgias</i>	363
<i>Gene delivery by intrathecal route</i>	363
<i>Gene transfer for delivery of analgesics to the spinal nerve roots</i>	364
<i>Gene therapy of peripheral neuropathic pain</i>	365
<i>Gene transfer by injections into the brain substance</i>	366
Targets for gene therapy of pain.....	366
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	366
<i>Gene therapy for producing enkephalin to block pain signals</i>	366
<i>Targeting nuclear factor-κB</i>	367
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	367
Potential applications of gene therapy for management of pain.....	368
Concluding remarks on gene therapy for pain.....	368
Gene therapy for psychiatric disorders	369
Gene therapy for depression	369
Gene therapy for enhancing cognition after stress.....	370
Gene therapy against fear disorders.....	370
Companies involved in gene therapy of neurological disorders.....	370

7. Gene Therapy of Cardiovascular Disorders	373
Introduction	373
Techniques of gene transfer to the cardiovascular system	373
Direct plasmid injection into the myocardium	374
Catheter-based systems for vector delivery.....	374
Ultrasound microbubbles for cardiovascular gene delivery	375
Vectors for cardiovascular gene therapy	375
<i>AAV vectors for therapeutic delivery to the heart</i>	375
<i>Adenoviral vectors for cardiovascular diseases</i>	376
<i>Molecular cardiac surgery with recirculating delivery of AAV vectors</i>	376
<i>Plasmid DNA-based delivery in cardiovascular disorders</i>	376
Gene therapy for counteracting hypoxia in myocardial ischemia.....	376
Therapeutic angiogenesis vs vascular growth factor therapy.....	377
Gene painting for delivery of targeted gene therapy to the heart	377
Gene delivery to vascular endothelium	378
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	378
Vascular stents for gene delivery	379
Gene therapy for genetic cardiovascular disorders	379
Catecholaminergic polymorphic ventricular tachycardia.....	379
Genetic disorders predisposing to atherosclerosis.....	380
Familial hypercholesterolemia.....	381
Apolipoprotein E deficiency.....	382
Hypertension.....	383
Genetic factors for myocardial infarction	383
Acquired cardiovascular diseases	384
Coronary artery disease with angina pectoris.....	384
<i>Ad5FGF-4</i>	384
Gene therapy for improving long-term CABG patency rates.....	385
Ischemic heart disease with myocardial infarction	385
<i>Gene therapy and angiogenesis in ischemic heart disease</i>	386
<i>Induction of angiogenesis in myocardium by HEXIM1 re-expression</i>	386
<i>Myocardial repair with IGF-1 therapy</i>	387
<i>Metalloproteinase-2 inhibitor gene therapy</i>	387
<i>miRNA gene therapy for ischemic heart disease</i>	388
Congestive heart failure.....	388

<i>Rationale of gene therapy in CHF</i>	388
<i>AAV-mediated gene transfer for CHF</i>	389
<i>AngioCell gene therapy for CHF</i>	389
<i>β-ARKct gene therapy</i>	390
<i>Elevating cardiac dATP by gene therapy to improve cardiac function</i>	390
<i>Elevating cardiac adenyl cylase type 6 to improve cardiac function</i>	391
<i>Intracoronary adenovirus-mediated gene therapy for CHF</i>	392
<i>nNOS gene transfer in CHF</i>	392
Cardiomyopathies.....	392
Cardiac conduction disturbances.....	393
<i>Gene transfer approaches for biological pacemakers</i>	393
<i>Genetically engineered biological pacemakers</i>	394
Gene therapy and heart transplantation.....	394
Hyperlipidemia and hypercholesterolemia.....	395
<i>Antisense approach to hypertriglyceridemia</i>	395
<i>Cholesterol reduction by genetic engineering of PCSK9 gene</i>	395
<i>Inactivating variants in ANGPTL4 for lowering circulating triglycerides</i>	395
Peripheral arterial disease	396
Incidence and clinical features.....	396
Current management.....	396
Gene therapy for peripheral arterial disease.....	396
<i>Angiogenesis by gene therapy</i>	396
<i>HIF-1α gene therapy for peripheral arterial disease</i>	397
<i>HGF gene therapy for peripheral arterial disease</i>	397
Prevention of restenosis after angioplasty.....	398
<i>Antisense approaches</i>	398
<i>Gene therapy to prevent restenosis after angioplasty</i>	399
<i>hTIMP-1 gene therapy to prevent intimal hyperplasia</i>	400
<i>miRNA-based gene therapy for restenosis</i>	400
<i>NOS gene therapy for restenosis</i>	401
<i>Techniques of gene therapy for restenosis</i>	401
Maintaining vascular patency after surgery.....	402
Companies involved in gene therapy of cardiovascular diseases	402
Future of gene therapy of cardiovascular disorders.....	403
8. Gene therapy of viral infections	405
Introduction	405
Acquired Immunodeficiency Syndrome (AIDS)	405
Current management of AIDS.....	405
Gene therapy strategies in HIV/AIDS.....	406
<i>HIV/AIDS vaccines</i>	406
<i>Insertion of protective genes into target cells</i>	407
Cell/gene therapies for HIV/AIDS.....	408
<i>Transplantation of genetically modified T cells</i>	408
<i>Transplantation of genetically modified hematopoietic cells</i>	409
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells</i>	410
Gene editing for HIV-1.....	410
Inhibition of HIV-1 replication by lentiviral vectors.....	410
<i>VRX496-T</i>	411
Intracellular immunization.....	411
Engineered cellular proteins such as soluble CD4s.....	412
Intracellular antibodies.....	412
Anti-rev single chain antibody fragment.....	412
Use of genes to chemosensitize HIV-1 infected cells.....	412
Autocrine interferon (INF)- β production by somatic cell gene therapy.....	413
Antisense approaches to AIDS.....	413
<i>RNA decoys</i>	413
<i>Antisense oligodeoxynucleotides</i>	413
<i>RNA decoys</i>	413
<i>Ribozymes</i>	414
RNAi applications in HIV/AIDS.....	414
<i>siRNA-directed inhibition of HIV-1 infection</i>	415
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	415
<i>Bispecific siRNA constructs</i>	415
<i>Targeting CXCR4 with siRNAs</i>	416
<i>Targeting CCR5 with siRNAs</i>	416
Companies involved in developing gene therapy for HIV/AIDS.....	417
Conclusions regarding gene therapy of HIV/AIDS.....	417
Genetic vaccines for other viral infections	418
Cytomegalic virus infections.....	418
Viral hepatitis.....	419

Vaccine for hepatitis B	419
Vaccine for hepatitis C	419
Gene therapy for hepatitis C	419
Vaccine for herpes simplex virus	420
DNA vaccine against rabies	420
DNA vaccine for Ebola	421
Vaccines for avian influenza	421
<i>Future prospects of DNA vaccines for avian influenza</i>	422
<i>Human trial of a DNA vaccine for avian influenza</i>	422
Companies developing genetic vaccines for infections other than AIDS	423
9. Research, Development and Future of Gene Therapy	425
Basic research in gene therapy	425
R & D in gene therapy	425
Animal models of human diseases for gene therapy research	426
<i>Lentiviral transgenesis</i>	426
Financing research and development	426
Role of the NIH in gene therapy research	426
National Gene Vector Laboratories	426
Funding of gene therapy research in Europe	427
<i>Gene therapy funding in Horizon 2020 of European Commission</i>	427
Financing by the industry	428
Clinical trials in gene therapy	428
Clinical trials worldwide	428
<i>Clinical trials in cancer gene therapy</i>	429
<i>Trials of gene therapy for neurological disorders</i>	429
<i>Clinical trials for genetic disorders</i>	429
<i>Clinical trials in cardiovascular gene therapy</i>	429
<i>Clinical trials for infectious diseases</i>	429
<i>Gene therapy for other disorders</i>	429
Clinical trials in the US	430
Vectors used in gene therapy clinical trials	430
<i>Vector analytics for clinical trials using rAAV vectors</i>	431
Gene therapy in China	431
Future of gene therapy	432
How to improve gene therapy	432
International Gene Therapy Consortium	433
Future opportunities and challenges for gene therapy	434
Promising areas of application of gene therapy	435
<i>Neurological disorders</i>	435
<i>Gene therapy of cardiovascular disorders</i>	436
<i>Cancer gene therapy</i>	437
Personalized gene therapy	438
10. Regulatory, Safety, Ethical Patent Issues of Gene Therapy	439
Regulation of gene therapy in the United States	439
US Federal guidelines for research involving recombinant DNA molecules	439
Regulation of gene therapy in US	439
Implantation of genetically manipulated cells	439
<i>Modification of oocytes for use in IVF</i>	440
Clinical trials in gene therapy	440
Cell and gene therapy INDs placed on hold by the FDA	440
Do-it-yourself gene therapy	441
Regulation of gene therapy in Europe	441
European Union	441
Regulation of gene therapy in Germany	442
<i>Preclinical research</i>	443
<i>Clinical Trials</i>	443
Marketing authorization	444
Regulation of gene therapy in the United Kingdom	444
Regulation of gene therapy in France	445
Regulation of gene therapy in Italy	445
Regulation of gene therapy in the Netherlands	446
Gene therapy regulation in Switzerland	447
Regulation of gene therapy in Australia	447
Regulation of gene therapy in Japan	448
Regulation of gene therapy in China	449
Safety issues of gene transfer	449
Adverse effects of retroviral vectors	449
<i>Insertional mutagenesis</i>	449
Adverse effects of HSV vectors	450

<i>Neurotoxicity of HSV vectors</i>	450
<i>Hepatotoxicity of HSV-tk/ganciclovir approach</i>	451
Adverse effects of adenoviral vectors	451
<i>Inflammatory effects of adenoviruses in lungs</i>	451
<i>Inflammatory effects involving the liver</i>	451
<i>Induction of immune response by adenoviral vectors</i>	452
<i>Impairment of adrenocortical steroidogenesis</i>	452
<i>Adverse effects of AAV vectors</i>	452
Toxicity associated with cationic lipid-mediated gene transfer	453
Toxicity of lipopolysaccharides	453
Potential side effects of RNAi gene therapy	453
Role of molecular diagnostics in safety of gene therapy	454
Quality control of vectors	454
<i>Testing for retroviruses</i>	454
<i>Adenoviral vectors</i>	455
<i>Replication competent viruses</i>	455
Genetic characteristics of viral vectors	455
Concluding remarks about safety of viral vectors	455
Ethical aspects of gene therapy	456
The lay consumer's view of somatic gene therapy ethics	456
Ethical aspects of clinical trials	457
Regulatory and ethical issues for in utero gene therapy	457
Ethical aspects of germline gene therapy	457
Ethical aspects of mitochondrial replacement therapy	458
Ethical aspects of gene editing	459
<i>Ethical aspects of clinical trials of germline editing</i>	459
<i>Gene editing in the UK</i>	459
<i>Gene editing in the US</i>	460
<i>UNESCO's view on gene editing in humans</i>	461
Germline gene therapy for genetic enhancement	462
Athletic enhancement by genetic engineering	462
<i>Gene doping in sports</i>	462
<i>Gene transfer methods used for enhancing physical performance</i>	462
<i>Adverse effect of genetic engineering</i>	464
<i>Problems in detecting genetic manipulations in athletes</i>	465
<i>Ethical dilemma</i>	465
Gene therapy patents	466
CRISP/Cas9 patents	466
11. Markets for Gene Therapy	469
Introduction	469
Gene therapy markets in various regions of the world	469
Gene therapy markets according to therapeutic areas	470
Cancer gene therapy market	470
Markets for gene therapy of genetic disorders	471
Markets for DNA vaccines	471
DNA vaccines markets according to technologies	471
DNA vaccines markets according to therapeutic indications	472
DNA vaccines markets according to geographical areas	472
Competing treatments	473
Antisense	473
RNAi	473
Cell therapy	474
Strategies for developing gene therapy markets	474
<i>Collaboration with pharmaceutical companies</i>	474
<i>Collaboration with companies developing cell-based therapies</i>	474
<i>Collaboration with academic gene therapy centers</i>	474
<i>Developing safer and cost-effective gene medicines</i>	474
<i>Intellectual property and commercialization of gene therapy</i>	475
<i>Overcoming obstructions to the development of gene therapy</i>	475
Unmet needs in gene therapy	476
Promises and challenges for the development of gene therapy	477
Development of gene therapy market in China	477
Challenges of developing gene therapy in the USA	477
Challenges of developing gene therapy in the European Union	477
12. References	479

Tables

Table 1-1: Landmarks in development of gene therapy.....	23
Table 2-1: Classification of methods of gene therapy.....	35
Table 2-2: A comparison of various physical methods of gene transfer	37
Table 2-3: Experimental applications of gene transfer by electroporation	38
Table 2-4: CRISPR vs other gene editing tools.....	49
Table 2-5: Companies developing CRISPR technology	58
Table 2-6: An overview of characteristics of commonly used viral vectors	63
Table 2-7: Companies using viral vectors.....	76
Table 2-8: Companies using nonviral vectors	95
Table 2-9: Target organs for nonviral gene therapy methods.	97
Table 2-10: Potential routes for administration of DNA	105
Table 2-11: Companies with gene delivery devices/ technologies.....	106
Table 2-12: Strategies for targeted gene therapy	108
Table 2-13: Animal experimental studies of in vivo gene delivery with polymer systems.....	109
Table 2-14: Approaches to controlling gene expression in gene therapy	110
Table 2-15: Companies with regulated/targeted gene therapy and special techniques	112
Table 2-16: Potential applications of human germline genome modification	114
Table 2-17: Applications of molecular diagnostics in gene therapy	127
Table 2-18: Advantages of gene therapy compared with protein therapy	129
Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis	135
Table 3-2: Gene therapy strategies for osteoarthritis.....	137
Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus.....	143
Table 3-4: Indications for gastrointestinal gene therapy	150
Table 3-5: Hematological disorders that can be potentially treated by gene therapy.....	152
Table 3-6: Clinical trials of gene therapy for hemophilia A and B.....	153
Table 3-7: Companies involved in gene therapy of hematological disorders.....	164
Table 3-8: Techniques of gene transfer to the kidneys.....	170
Table 3-9: Gene therapy in animal experimental models of renal disease.....	172
Table 3-10: Applications of gene therapy in ophthalmological disorders	180
Table 3-11: Companies developing gene therapy for eye disorders	197
Table 3-12: Strategies for gene delivery to the lungs	200
Table 3-13: Companies developing gene therapy for pulmonary disorders	209
Table 4-1: Genetic disorders that are being investigated for gene therapy	221
Table 4-2: X-linked immunodeficiency disorders	223
Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy	228
Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy	247
Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders	265
Table 5-1: Strategies for cancer gene therapy	267
Table 5-2: Cell-based gene therapy for cancer	272
Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines	280
Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy	284
Table 5-5: Mutation compensation strategies used clinically	285
Table 5-6: Companies developing oncolytic viruses	300
Table 5-7: Strategies for gene therapy of malignant brain tumors.....	304
Table 5-8: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	310
Table 5-9: Clinical trials of gene therapy in ovarian cancer.....	312
Table 5-10: Gene therapy for malignant melanoma.....	313
Table 5-11: Clinical trials of gene therapy for prostate cancer	318
Table 5-12: Companies involved in cancer gene therapy.....	323
Table 6-1: Example of potential indications for gene therapy of neurologic disorder	327
Table 6-2: Methods of gene transfer as applied to neurologic disorders	328
Table 6-3: Gene therapy techniques applicable to Parkinson disease	334
Table 6-4: Companies developing gene therapy for Parkinson's disease.....	342
Table 6-5: Gene transfer in animal models of carotid artery restenosis.....	351
Table 6-6: Gene therapy strategies for vasospasm.....	351
Table 6-7: Neuroprotective gene therapy in animal stroke models	353
Table 6-8: Experimental gene therapy approaches for relief of pain	363
Table 6-9: Companies involved in gene therapy of neurological disorders	371
Table 7-1: Cardiovascular disorders that are potential indications for gene therapy.....	373
Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system.....	374
Table 7-3: Companies involved in gene therapy of cardiovascular diseases	402
Table 8-1: Strategies for gene therapy of AIDS	406
Table 8-2: Companies involved in developing gene therapy for HIV/AIDS	417
Table 8-3: Companies developing genetic vaccines for infections other than AIDS	423
Table 9-1: Geographical distribution of gene therapy clinical trials	428
Table 9-2: Opportunities and challenges for gene therapy and resources needed	435
Table 9-3: Potential applications of gene therapy in disorders of the nervous system	436
Table 10-1: Genes that may be used for performance enhancement	463
Table 11-1: Gene therapy market according to regions/countries – 2017 to 2027	469

Table 11-2: Gene therapy markets according to therapeutic areas – 2017 to 2027.....	470
Table 11-3: Cancer gene therapy market according to type of cancer - 2017 to 2027.....	470
Table 11-4: Gene therapy market for selected genetic disorders - 2017 to 2027.....	471
Table 11-5: DNA vaccines markets according to technologies - 2017 to 2027.....	472
Table 11-6: DNA vaccines markets according to therapeutic indications - 2017 to 2027.....	472
Table 11-7: DNA vaccines markets according to geographical areas - 2017 to 2027.....	472

Figures

Figure 1-1: Relation of gene therapy to other biotechnologies	25
Figure 1-2: Relationship of DNA, RNA and protein in the cell	29
Figure 2-1: Ex vivo and in vivo techniques of gene therapy.....	36
Figure 2-2: Structure of the Helios gene gun.....	42
Figure 2-3: A scheme of CRISPR/Cas9 gene editing	48
Figure 2-4: Use of CRISPR-Cas9 for hereditary hearing loss.....	56
Figure 2-5: Categories of rAAV-based gene therapy strategies	66
Figure 2-6: Bacteria plus nanoparticles for drug delivery into cells	93
Figure 2-7: Schematic of suppression of gene expression by RNAi	124
Figure 3-1: Retina and routes of administration of gene therapy for retinal disorders	186
Figure 4-1: Targeted gene correction of α 1-antitrypsin deficiency by iPSCs	231
Figure 4-2: Application of CRISPR-Cas9 in a mouse model of DMD.....	254
Figure 4-3: Techniques for mitochondrial nuclear transfer.....	263
Figure 5-1: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	290
Figure 5-2: Gene therapy approaches for pancreatic cancer	320
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels	336
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage.....	356
Figure 9-1: Product development cycle in gene therapy	425
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US.....	430
Figure 9-3: Proportions of various vectors used in gene therapy trials	430
Figure 10-1: Evaluation system of gene therapy clinical studies in Japan	448
Figure 11-1: Unmet needs in gene therapy	476